• About us

    About us

    Futura Medical is the developer of innovative sexual health products, including lead product Eroxon®. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products. 

    Explore this section
    • Who we are
    • Our business model
    • Our strategy
    • Board of directors
  • Eroxon®

    Eroxon®

    Our lead product is Eroxon®a clinically proven breakthrough treatment for erectile dysfunction

    • What is Eroxon®
    • Eroxon® at a glance
    • Clinical data
    • Marketplace
    • Commercial partners
    • Commercialisation
    • Eroxon® FAQs
  • PIPELINE

    PIPELINE

    Futura has two new products in its development pipeline, Eroxon® Intense and WSD4000 for the treatment of sexual dysfunction in men and women.

    • Eroxon® Intense
    • WSD4000 - For the treatment of sexual dysfunction in women
  • Investor centre

    Investor centre

    Futura has a proven track record in delivery and completion of Research & Development projects up to value inflection points at which they are suitable for commercialisation partners.

    WEBCASTS

    Explore this section
    • Share price chart
    • Corporate documentation
    • Videos and webcasts

      Videos and webcasts

      • Videos
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre

      Shareholder centre

      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
      • Investor FAQs
      • Analyst Research
    • Corporate Governance
    • AIM rule 26
  • Media

    Media

    This section contains the latest RNS, news and videos.

    Explore this section
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
  • About us
    • Who we are
    • Our business model
    • Our strategy
    • Board of directors
  • Eroxon®
    • What is Eroxon®
    • Eroxon® at a glance
    • Clinical data
    • Marketplace
    • Commercial partners
    • Commercialisation
    • Eroxon® FAQs
  • PIPELINE
    • Eroxon® Intense
    • WSD4000 - For the treatment of sexual dysfunction in women
  • Investor centre
    • Share price chart
    • Corporate documentation
    • Videos and webcasts
      • Videos
        • Futura Medical CEO James Barder on Futura’s 2024 strong growth, maiden profit and 2025 plans
        • Futura Medical announces enhanced Eroxon Gel for ED and female sexual dysfunction product
      • Webcasts
    • RNS
    • Alert service
    • Shareholder centre
      • Investor contacts and advisors
      • Shareholder information
      • Financial calendar
        • Notice of results for for the year ended 31 December 2024
      • Investor FAQs
      • Analyst Research
        • 2025
          • Panmure Liberum - Futura Medical Learnings will be Key
          • Trinity Delta Futura Medical Home use study supports WSD4000 development
    • Corporate Governance
    • AIM rule 26
  • Media
    • News
    • Event calendar
    • RNS
    • Videos
    • Alert service
  • Contact us
    Site essentials

    Site essentials

    • Home
    • Site essentials

    ©2025 Futura Medical

    • Sitemap
    • Contact us
    • Accessibility
    • Terms of use
    • Privacy & cookies policies

    ©2025 Futura Medical

    Designed and developed by
    jonesandpalmer.co.uk